$NKTR

Pomerantz LLP filed securities fraud class action against Nektar Therapeutics, alleging false statements about clinical trial enrollment procedures led to trial failure and stock decline.

Class action lawsuit filed against $NKTX alleging executives made false statements about REZOLVE-AA trial integrity. Investors urged to join by May 5, 2026 deadline.

Shareholder lawsuits target Kyndryl and uniQure with lead plaintiff deadlines approaching April 2026. Investors must act quickly to join litigation.

Nektar Therapeutics faces securities lawsuit over REZOLVE-AA trial enrollment irregularities. Eligible investors have until May 5, 2026 to pursue compensation.

Class action lawsuit filed against Nektar Therapeutics alleging executives made false statements about REZOLVE-AA trial enrollment, claiming protocol violations negatively impacted results.

Abivax and Nektar Therapeutics are positioned as acquisition targets with promising drug candidates and upcoming phase 3 trial data, attracting interest from major pharmaceutical companies.

Nektar Therapeutics faces class action lawsuit over alleged failure to disclose enrollment protocol violations in failed Phase 2b REZOLVE-AA trial, triggering 8% stock decline.

Shareholder lawsuits against Nektar Therapeutics ($NKTR) and Eos Energy ($EOSE) allege clinical trial and production capacity disclosure failures, with lead plaintiff deadlines in April-May 2026.

Class action lawsuit filed against Nektar Therapeutics alleging materially false statements regarding REZOLVE-AA trial enrollment protocols, claiming compromised trial integrity.

Nektar faces securities litigation over alleged misstatements about REZOLVE-AA trial enrollment practices. Stock fell 7.77% after trial failure announcement.

Rosen Law Firm pursues class action against Eos Energy Enterprises for alleged false statements about operations and guidance. Investors must act by May 5, 2026 deadline.

Rosen Law Firm files securities class actions against Nektar Therapeutics, Enphase Energy, and Aquestive Therapeutics. Investors have until May 5, 2026 to join.

Rosen Law Firm filed securities class action against Enphase Energy ($ENPH) alleging false statements on inventory and renewable energy credits. Deadline April 20, 2026.

Rosen Law Firm filed class action against Aquestive Therapeutics alleging false statements about product development and regulatory matters. Eligible investors should act before deadline.

Class action lawsuit filed against $NKTX alleging executives made false statements about REZOLVE-AA trial enrollment protocols, potentially harming investor value.

Law firm investigates $NKTR over December trial failure disclosure. Stock dropped 7.8% after alopecia areata Phase 2b study missed endpoints due to ineligible patients.

Nektar Therapeutics faces securities class action over alleged misstatements about REZOLVE-AA trial, with stock falling 7.77% after trial failure announcement.

Law firm Bernstein Liebhard announces class action against $NKTR over alleged misrepresentations regarding Phase 2b trial results, affecting investors from February to December 2025.

Rosen Law Firm sues Nektar Therapeutics for alleged false statements about clinical trial protocols, seeking damages for injured investors as litigation moves forward.

Schall Law Firm launches class action against $NKTR for alleged securities fraud tied to REZOLVE-AA trial protocol violations and misstatements between February-December 2025.